FIELD: medicine.
SUBSTANCE: present invention relates to medicine, namely cancer, and can be used to treat prostate cancer. To do this, the source of a polypeptide comprising a limited MHC class I and/or MHC class II T-cell epitope of native shiny shell (zona pellucida) 3 (ZP3) for the manufacture of a medicament for the treatment of prostate cancer.
EFFECT: use of the invention enables an immunotherapy using tumor-associated antigens in patients with prostate cancer who have prostate cancer cells express ZP3.
14 cl, 6 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CDC45L PEPTIDES AND VACCINES CONTAINING SAME | 2010 |
|
RU2562160C2 |
| MODIFIED MELK PEPTIDES AND VACCINES CONTAINING LATTER | 2011 |
|
RU2580035C2 |
| IMMUNOTHERAPEUTIC METHODS FOR TREATING AND/OR PREVENTING LUNG CANCER | 2018 |
|
RU2793972C2 |
| TUMOR POLYPEPTIDE ISOLATED FROM PROSTATE AND POLYNUCLEOTIDE ENCODING THEREOF | 1999 |
|
RU2234942C2 |
| PRIME-BOOST MODES INVOLVING INTRODUCTION OF AT LEAST ONE MRNA STRUCTURE | 2016 |
|
RU2742993C2 |
| COMPOSITIONS AND METHODS FOR TARGET ELIMINATION OF MUTATION ESCAPE IN TARGET CANCER THERAPY | 2008 |
|
RU2505313C2 |
| CDCA1 EPITOPE PEPTIDES AND VACCINES CONTAINING SAME | 2009 |
|
RU2502740C2 |
| EPITOPIC PEPTIDES RAB6KIFL/KIF20A AND VACCINES CONTAINING THEM | 2009 |
|
RU2532105C2 |
| COMBINATION OF RECOMBINANT MICROBACTERIUM AND BIOLOGICALLY ACTIVE AGENT AS VACCINE | 2005 |
|
RU2495677C2 |
| T-CELLS WITH TRANSDUCED ANTIGEN APPLIED AS ANTIGEN DELIVERY SYSTEMS | 2003 |
|
RU2330884C2 |
